Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-1008 (tigatuzumab) plus sorafenib vs sorafenib in advanced hepatocellular carcinoma
jRCT2080221104Phase 2
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of tigatuzumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd.
02
Drugs
tigatuzumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080221104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221104.